Juenger, Stephanie T., Reinecke, David ORCID: 0000-0002-3298-9517, Meissner, Anna-Katharina, Goldbrunner, Roland and Grau, Stefan (2022). Resection of symptomatic non-small cell lung cancer brain metastasis in the setting of multiple brain metastases. J. Neurosurg., 136 (6). S. 1576 - 1583. ROLLING MEADOWS: AMER ASSOC NEUROLOGICAL SURGEONS. ISSN 1933-0693

Full text not available from this repository.

Abstract

OBJECTIVE Current guidelines primarily suggest resection of brain metastases (BMs) in patients with limited lesions. With a growing number of highly effective local and systemic treatment options, this view may be challenged. The purpose of this study was to evaluate the role of metastasectomy, disregarding BM count, in a comprehensive treatment setting. METHODS In this monocentric retrospective analysis, the authors included patients who underwent resection for at least 1 BM and collected demographic, clinical, and tumor-associated parameters. Prognostic factors for local control and overall survival (OS) were analyzed with the log-rank test and Cox proportional hazards analysis. RESULTS The authors analyzed 216 patients. One hundred twenty-nine (59.7%) patients were diagnosed with a single/ solitary BM, whereas 64 (29.6%) patients had 2-3 BMs and the remaining 23 (10.6%) had more than 3 BMs. With resection of symptomatic BMs, a significant improvement in Karnofsky Performance Scale (KPS) was achieved (p < 0.001), thereby enabling adjuvant radiotherapy for 199 (92.1%) patients and systemic treatment for 119 (55.1%) patients. During follow-up, 83 (38.4%) patients experienced local recurrence. BM count did not significantly influence local control rates. By the time of analysis, 120 (55.6%) patients had died; the leading cause of death was systemic tumor progression. The mean (range) OS after surgery was 12.7 (0-88) months. In univariate analysis, the BM count did not influence OS (p = 0.844), but age < 65 years (p = 0.007), preoperative and postoperative KPS >= 70 (p = 0.002 and p = 0.005, respectively), systemic metastases other than BM (p = 0.004), adjuvant radiation therapy (p < 0.001), and adjuvant systemic treatment (p < 0.001) were prognostic factors. In regression analysis, the presence of extracranial metastases (HR 2.30, 95% CI 1.53-3.48, p < 0.001), adjuvant radiation therapy (HR 0.97, 95% CI 0.23-0.86, p = 0.016), and adjuvant systemic treat- ment (HR 0.37, 95% CI 0.25-0.55, p < 0.001) remained as independent factors for survival. CONCLUSIONS Surgery for symptomatic BM from non-small cell lung cancer may be indicated even for patients with multiple lesions in order to alleviate their neurological symptoms and to consequently facilitate further treatment.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Juenger, Stephanie T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Reinecke, DavidUNSPECIFIEDorcid.org/0000-0002-3298-9517UNSPECIFIED
Meissner, Anna-KatharinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Goldbrunner, RolandUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Grau, StefanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-658577
DOI: 10.3171/2021.7.JNS211172
Journal or Publication Title: J. Neurosurg.
Volume: 136
Number: 6
Page Range: S. 1576 - 1583
Date: 2022
Publisher: AMER ASSOC NEUROLOGICAL SURGEONS
Place of Publication: ROLLING MEADOWS
ISSN: 1933-0693
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
STEREOTACTIC RADIOSURGERY; SURGICAL RESECTION; EGFR MUTATIONS; OPEN-LABEL; SINGLE; RADIOTHERAPY; MELANOMA; SURGERY; MULTICENTER; SURVIVALMultiple languages
Clinical Neurology; SurgeryMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/65857

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item